SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial

SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial

Background: The antiviral effects of Novaferon, a potent antiviral protein drug, on COVID-19 was evaluated in the laboratory, and in a randomized, open-label, parallel-group trial. Methods: In the laboratory, Novaferon's inhibition of viral replication in cells infected with SARS-CoV-2, and pre...

Full description

Bibliographic Details
Main Authors: Fang Zheng, Yanwen Zhou, Zhiguo Zhou, Fei Ye, Baoying Huang, Yaxiong Huang, Jing Ma, Qi Zuo, Xin Tan, Jun Xie, Peihua Niu, Wenlong Wang, Yun Xu, Feng Peng, Ning Zhou, Chunlin Cai, Wei Tang, Xinqiang Xiao, Yi Li, Zhiguang Zhou, Yongfang Jiang, Yuanlin Xie, Wenjie Tan, Guozhong Gong
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:International Journal of Infectious Diseases
Subjects:
COVID-19
SARS-CoV-2
Novaferon
Antiviral drug
Lopinavir/Ritonavir
Viral clearance
Online Access:http://www.sciencedirect.com/science/article/pii/S120197122030597X

Internet

http://www.sciencedirect.com/science/article/pii/S120197122030597X

Similar Items